XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Fundamental Analysis
NASDAQ:XOMAP - Nasdaq - US98419J3059 - Currency: USD
Overall XOMAP gets a fundamental rating of 4 out of 10. We evaluated XOMAP against 557 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMAP while its profitability can be described as average. XOMAP is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
XOMAP had negative earnings in the past year.
XOMAP had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XOMAP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMAP reported negative operating cash flow in multiple years.
1.2 Ratios
XOMAP has a Return On Assets of -8.74%. This is amongst the best in the industry. XOMAP outperforms 84.74% of its industry peers.
XOMAP has a better Return On Equity (-21.96%) than 83.66% of its industry peers.
The Return On Invested Capital of XOMAP (0.19%) is better than 91.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.74% | ||
| ROE | -21.96% | ||
| ROIC | 0.19% |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of XOMAP (1.03%) is better than 91.56% of its industry peers.
The Profit Margin and Gross Margin are not available for XOMAP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.03% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XOMAP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, XOMAP has more shares outstanding
Compared to 5 years ago, XOMAP has more shares outstanding
Compared to 1 year ago, XOMAP has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.94, we must say that XOMAP is in the distress zone and has some risk of bankruptcy.
XOMAP's Altman-Z score of -5.94 is on the low side compared to the rest of the industry. XOMAP is outperformed by 63.55% of its industry peers.
XOMAP has a Debt/Equity ratio of 1.18. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.18, XOMAP is doing worse than 79.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.94 |
ROIC/WACC0.02
WACC8.33%
2.3 Liquidity
A Current Ratio of 5.54 indicates that XOMAP has no problem at all paying its short term obligations.
The Current ratio of XOMAP (5.54) is comparable to the rest of the industry.
XOMAP has a Quick Ratio of 5.54. This indicates that XOMAP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XOMAP (5.54) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.54 | ||
| Quick Ratio | 5.54 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.50% over the past year.
Looking at the last year, XOMAP shows a very strong growth in Revenue. The Revenue has grown by 663.79%.
Measured over the past years, XOMAP shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%
3.2 Future
XOMAP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.94% yearly.
XOMAP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.09% yearly.
EPS Next Y73.1%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
EPS Next 5YN/A
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XOMAP. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 602.78, the valuation of XOMAP can be described as expensive.
Based on the Price/Forward Earnings ratio, XOMAP is valued cheaply inside the industry as 87.07% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.13. XOMAP is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 602.78 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XOMAP is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 269.05 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates XOMAP does not grow enough to justify the current Price/Earnings ratio.
XOMAP's earnings are expected to grow with 39.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.15%
EPS Next 3Y39.94%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 8.35%, XOMAP is a good candidate for dividend investing.
XOMAP's Dividend Yield is rather good when compared to the industry average which is at 117.51. XOMAP pays more dividend than 99.64% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, XOMAP pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 8.35% |
5.2 History
XOMAP has been paying a dividend for over 5 years, so it has already some track record.
XOMAP has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
5.3 Sustainability
XOMAP has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-29.44%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (6/13/2025, 8:00:02 PM)
25.8229
+0.24 (+0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners62.7%
Inst Owner ChangeN/A
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap309.10M
Analysts82
Price Target68.74 (166.2%)
Short Float %0.01%
Short Ratio0.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 8.35% |
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-29.44%
Div Incr Years0
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.13%
Min EPS beat(2)-45.44%
Max EPS beat(2)119.7%
EPS beat(4)2
Avg EPS beat(4)56.23%
Min EPS beat(4)-256.98%
Max EPS beat(4)407.67%
EPS beat(8)3
Avg EPS beat(8)22.51%
EPS beat(12)3
Avg EPS beat(12)-16.39%
EPS beat(16)5
Avg EPS beat(16)-21.54%
Revenue beat(2)1
Avg Revenue beat(2)59.22%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.22%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)22.27%
Revenue beat(12)6
Avg Revenue beat(12)0.36%
Revenue beat(16)7
Avg Revenue beat(16)-7.52%
PT rev (1m)-4.98%
PT rev (3m)-25.49%
EPS NQ rev (1m)-37.92%
EPS NQ rev (3m)-6.56%
EPS NY rev (1m)0%
EPS NY rev (3m)1.59%
Revenue NQ rev (1m)22.56%
Revenue NQ rev (3m)15.48%
Revenue NY rev (1m)36.77%
Revenue NY rev (3m)31.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 602.78 | ||
| P/S | 6.96 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.65 | ||
| P/tB | 5.22 | ||
| EV/EBITDA | 269.05 |
EPS(TTM)-1.14
EYN/A
EPS(NY)0.04
Fwd EY0.17%
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS3.71
BVpS7.07
TBVpS4.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.74% | ||
| ROE | -21.96% | ||
| ROCE | 0.24% | ||
| ROIC | 0.19% | ||
| ROICexc | 0.36% | ||
| ROICexgc | 0.49% | ||
| OM | 1.03% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 82.05 | ||
| Cap/Depr | 2651.64% | ||
| Cap/Sales | 45.45% | ||
| Interest Coverage | 0.04 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.54 | ||
| Quick Ratio | 5.54 | ||
| Altman-Z | -5.94 |
F-Score5
WACC8.33%
ROIC/WACC0.02
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
EPS Next Y73.1%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
EPS Next 5YN/A
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A
EBIT growth 1Y102%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y16.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.67%
OCF growth 3YN/A
OCF growth 5YN/A